Literature DB >> 15994874

The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

M E Baser1, L Kuramoto, R Woods, H Joe, J M Friedman, A J Wallace, R T Ramsden, S Olschwang, E Bijlsma, M Kalamarides, L Papi, R Kato, J Carroll, C Lázaro, F Joncourt, D M Parry, G A Rouleau, D G R Evans.   

Abstract

Neurofibromatosis 2 (NF2) patients with constitutional splice site NF2 mutations have greater variability in disease severity than NF2 patients with other types of mutations; the cause of this variability is unknown. We evaluated genotype-phenotype correlations, with particular focus on the location of splice site mutations, using mutation and clinical information on 831 patients from 528 NF2 families with identified constitutional NF2 mutations. The clinical characteristics examined were age at onset of symptoms of NF2 and number of intracranial meningiomas, which are the primary indices of the severity of NF2. Two regression models were used to analyse genotype-phenotype correlations. People with splice site mutations in exons 1-5 had more severe disease than those with splice site mutations in exons 11-15. This result is compatible with studies showing that exons 2 and 3 are required for self-association of the amino terminal of the NF2 protein in vitro, and that deletions of exons 2 and 3 in transgenic and knockout mouse models of NF2 cause a high prevalence of Schwann cell derived tumours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994874      PMCID: PMC1736092          DOI: 10.1136/jmg.2004.029504

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  53 in total

1.  NF2 gene deletion in a family with a mild phenotype.

Authors:  C López-Correa; J Zucman-Rossi; H Brems; G Thomas; E Legius
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

2.  Functional analysis of neurofibromatosis 2 (NF2) missense mutations.

Authors:  D H Gutmann; A C Hirbe; C A Haipek
Journal:  Hum Mol Genet       Date:  2001-07-01       Impact factor: 6.150

3.  Truncated NF2 proteins are not detected in meningiomas and schwannomas.

Authors:  M A Den Bakker; A A van Tilborg; J M Kros; E C Zwarthoff
Journal:  Neuropathology       Date:  2001-09       Impact factor: 1.906

4.  High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH.

Authors:  C E Bruder; C Hirvelä; I Tapia-Paez; I Fransson; R Segraves; G Hamilton; X X Zhang; D G Evans; A J Wallace; M E Baser; J Zucman-Rossi; M Hergersberg; E Boltshauser; L Papi; G A Rouleau; G Poptodorov; A Jordanova; H Rask-Andersen; L Kluwe; V Mautner; M Sainio; G Hung; T Mathiesen; C Möller; S M Pulst; H Harder; A Heiberg; M Honda; M Niimura; S Sahlén; E Blennow; D G Albertson; D Pinkel; J P Dumanski
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

5.  Defects in neurofibromatosis 2 protein function can arise at multiple levels.

Authors:  D H Gutmann; R T Geist; H m Xu; J S Kim; S Saporito-Irwin
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

6.  Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis.

Authors:  L K Su; C J Barnes; W Yao; Y Qi; P M Lynch; G Steinbach
Journal:  Am J Hum Genet       Date:  2000-08-03       Impact factor: 11.025

7.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

8.  Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus.

Authors:  M Sainio; J Jääskeläinen; H Pihlaja; O Carpén
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

9.  Effects of Nf2 missense mutations on schwannomin interactions.

Authors:  Daniel R Scoles; Mercy Chen; Stefan-M Pulst
Journal:  Biochem Biophys Res Commun       Date:  2002-01-11       Impact factor: 3.575

10.  Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.

Authors:  Michael E Baser; Erini V Makariou; Dilys M Parry
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

View more
  24 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Clinicopathologic assay of 15 tumor resections in a family with neurofibromatosis type 2.

Authors:  Salvatore Di Maio; Goran Mrak; Gordana Juric-Sekhar; Donald Born; Alessandra Mantovani; Laligam N Sekhar
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

Review 4.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Authors:  Thomas R Webb; Amanda S Joyner; Philip M Potter
Journal:  Drug Discov Today       Date:  2012-08-03       Impact factor: 7.851

Review 5.  The HIPPO pathway in gynecological malignancies.

Authors:  Dongying Wang; Jiaxing He; Junxue Dong; Thomas F Meyer; Tianmin Xu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

6.  Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2.

Authors:  Eiji Ito; Kiyoshi Saito; Hiroshi Yatsuya; Tetsuya Nagatani; Goro Otsuka
Journal:  Neurosurg Rev       Date:  2009-08-12       Impact factor: 3.042

7.  Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.

Authors:  Claire Forde; Andrew T King; Scott A Rutherford; Charlotte Hammerbeck-Ward; Simon K Lloyd; Simon R Freeman; Omar N Pathmanaban; Emma Stapleton; Owen M Thomas; Roger D Laitt; Stavros Stivaros; John-Paul Kilday; Grace Vassallo; Catherine McBain; Simon Kerrigan; Miriam J Smith; Martin G McCabe; Elaine F Harkness; D Gareth Evans
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

8.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20

Review 9.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

Review 10.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.